Michael Patterson

Michael Patterson is an experienced Clinical Specialty Representative in Neurology at Mayo Clinic Laboratories since January 2016. Previously, Patterson served as a Senior MS Sales Specialist at Novartis, where a successful launch of Gilenya, the first oral disease-modifying therapy for Multiple Sclerosis, took place in Oregon and Southwest Washington. Other roles include Area Business Manager at Acorda Therapeutics, successfully launching Ampyra, and Professional Sales Consultant at Bayer, focusing on expanding Betaseron utilization among Neurologists. Earlier career experience includes multiple positions at Novo Nordisk and an account representative role at 3M. Michael Patterson holds a Bachelor of Science degree in Journalism from Southern Illinois University, Carbondale.